ArticleScientific reports2026
Assessment of cold atmospheric pressure plasma therapy initiated at peak severity in a mouse model of radiation dermatitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation dermatitis (RD) is a common side effect of radiation therapy, potentially leading to treatment interruptions. This study evaluated the efficacy of cold atmospheric plasma (CAP) in a mouse model of RD, specifically focusing on treatment initiation at the peak of disease severity. As secondary objective, hyperspectral imaging (HSI) and optical coherence tomography (OCT), were evaluated as objective measures to monitor disease severity. RD was induced via gamma irradiation, with daily CAP treatment initiated at the peak severity. RD severity was monitored using macroscopic scoring and imaging. We found that CAP treatment initiated at the peak of disease did not result in a measurable improved healing under the tested conditions. HSI showed significant differences (p ≤ 0.05) between healthy and RD skin even beyond macroscopic scoring. OCT differentiated between healthy and diseased skin, however, no significant difference was observed after macroscopic healing. Our findings suggest that CAP therapy initiated at peak RD does not accelerate recovery. However, this result does not preclude potential efficacy of CAP when administered prophylactically or at the early onset of skin injury. The study underscores the critical importance of treatment timing and highlights HSI and OCT as potentially valuable non-invasive tools for objective RD assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.